Tóm tắt
Cập nhật về liệu pháp kháng kết tập tiểu cầu trong hội chứng mạch vành cấp
Trang chủ
CHUYÊN ĐỀ
Số phát hành:
Cập nhật về liệu pháp kháng kết tập tiểu cầu trong hội chứng mạch vành cấp
Hồ Huỳnh Quang Trí: Viện Tim TP. Hồ Chí Minh;
Nguyễn Lân Việt: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Xuất bản: tháng 11 1, 2014
Views: 1
Tài liệu tham khảo
1.
1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332:349-360.
2.
2. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
3.
3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
4.
4. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST elevation. N Engl J Med 2005;352:1179-1189
5.
5. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45.852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet 2005;366:1607-1621.
6.
6. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:296- 329.
7.
7. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - Executive summary. J Am Coll Cardiol 2007;50:652-726.
8.
8. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
9.
9. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: Benefits and limitations. Am Heart J 2008;156:S3-S9.
10.
10. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am JCardiol 2009;103[suppl]:27A- 34A.
11.
11. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436.
12.
12. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317.
13.
13. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
14.
14. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The randomised, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
15.
15. Bhatt DL, Cryer BL, Contant CF, et al, for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
16.
16. The FDA safety information and adverse event reporting program. www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm225843.htm.
17.
17. Collet JP, Cuisset T, Rangé G, et al, for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet
18.
therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.
19.
18. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942.
20.
19. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2012;126:875- 910.
21.
20. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST- elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-e140.
22.
21. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403.
23.
22. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735- 741.
24.
23. Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
25.
24. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856.
26.
25. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
27.
26. Wallentin L, Becker RC, Budaj A, et al, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
28.
27. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-554.
29.
28. Cannon CP, Harrington RA, James S, et al, for the PLATO Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-293.
30.
29. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLAtelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527 doi:10.1136/bmj.d3527